The Food and Drug Administration has not returned to inspect approximately 2,000 pharmaceutical manufacturing facilities since before the pandemic, potentially jeopardizing drug safety.
About 42% of the 4,700 plants registered for drug production have not been inspected since prior to the pandemic, raising contamination risks for critical medications.
Plants overdue for inspections, including many overseas, represent a significant risk according to FDA guidelines, emphasizing the need for urgent attention to drug safety.
As generic drugmakers face cost-cutting pressures, risks to quality standards increase, with serious implications for the safety of essential medications.
[
Collection
]
[
|
...
]